Tag: 300-400

On December 31, 2021, Mejia-Giraldo, Juan C.; Winkler, Robert; Puertas-Mejia, Miguel published an article.COA of Formula: C24H27NO2 The title of the article was Novel UV filters from Pentacalia pulchella extracts with photoprotective properties and antioxidant activity. And the article contained the following:

Most of the plant species found in the high mountain ecosystems of the tropics is unique and exceptional, because they have developed complex adaptations to survive in extreme environmental conditions, such as high levels of UVR and low temperatures of these ecol. environments. In an exploratory study carried out on some plants of this ecosystem, we found that one of the most promising species was the Pentacalia pulchella (Kunth) Cuatrec. (Asteraceae) an endemic plant of Colombia, which grows between 2500 and 3500 m.a.s.l. Therefore, the objective of this work was to evaluate the photoprotective, antioxidant, and chem. composition of extracts from the leaves of P. pulchella. Extracts showed good absorption coefficients in UVA-UVB, high content of total phenols, with antioxidant activity comparable to that obtained with butylhydroxytoluene (BHT). Finally, the formulation labeled “7” with 10% extract presented adequate sensory characteristics for topical use, good in vitro photoprotection values in the UVA-UVB range (SPF (Sun Protection Factor): 7.3 ± 0.9, UVAPF (UV A Protection Factor): 5.3 ± 0.6, λc 376), and antioxidant activity. The extract of P. pulchella has a high potential as a source of new natural solar filters. The experimental process involved the reaction of 2-Ethylhexyl 2-cyano-3,3-diphenylacrylate(cas: 6197-30-4).COA of Formula: C24H27NO2

The Article related to pentacalia caffeoylquinic acid hexose methyl linoleate octocrylene chlorophyll antioxidant, natural sunscreens, pentacalia pulchella, photoprotection, uva–uvb radiation, Placeholder for records without volume info and other aspects.COA of Formula: C24H27NO2

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On August 14, 2020, Feng, Shaojie; Xiong, Chenghe; Wang, Guirong; Wang, Subo; Jin, Guoxia; Gu, Guofeng published an article.Name: Bis(2,5-dioxopyrrolidin-1-yl) glutarate The title of the article was Exploration of Recombinant Fusion Proteins YAPO and YAPL as Carrier Proteins for Glycoconjugate Vaccine Design against Streptococcus pneumoniae Infection. And the article contained the following:

Pneumolysin (Ply), pneumococcal surface protein A (PspA), and pneumococcal surface adhesin A (PsaA) are promising cell surface protein antigen targets for Streptococcus pneumoniae (Spn) vaccine development. We designed and recombined 2 fusion proteins, named YAPO and YAPL, which contained the main antigenic epitopes of Ply, PspA, and PsaA. In-depth immunol. evaluations revealed that YAPO and YAPL had strong immunocompetence to be well-qualified potential carrier proteins. To verify this possibility, a serotype 3 Spn (ST3) capsular polysaccharide pentasaccharide was conjugated to each fusion protein to generate the resultant glycoconjugates. Immunol. studies in mice revealed that, as compared with TT conjugate, YAPO and YAPL conjugates provoked robust T-cell-dependent immune responses that could provide better recognition, in vitro efficient opsonophagocytosis, and in vivo effective protection against various serotypes of Spn. Collectively, YAPO and YAPL were identified as immunopotentiating carriers that could help convert immunol. inactive ST3 pentasaccharide into a T cell-dependent antigen and provide efficient and broad spectrum of immunoprotection coverage so as to formulate functional glycoconjugate vaccines against Spn infections. The experimental process involved the reaction of Bis(2,5-dioxopyrrolidin-1-yl) glutarate(cas: 79642-50-5).Name: Bis(2,5-dioxopyrrolidin-1-yl) glutarate

The Article related to streptococcus glycoconjugate vaccine yapo yapl carrier protein, streptococcus pneumoniae, carrier protein, fusion protein, glycoconjugate vaccine, immunoprotection, Placeholder for records without volume info and other aspects.Name: Bis(2,5-dioxopyrrolidin-1-yl) glutarate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On June 30, 2021, El Khoury, Rindala; Abboud, Marie; Michael-Jubeli, Rime; Yagoubi, Najet; Baillet-Guffroy, Arlette; Rizk, Toufic; Tfayli, Ali; Lteif, Roger published an article.COA of Formula: C24H27NO2 The title of the article was EBT3 Gafchromic film as a new substrate for in vitro evaluation of sun protection factor. And the article contained the following:

There exist different methods for the determination of sun protection factor (SPF) values for sunscreens. We aimed to develop a new in vitro method using EBT3 Gafchromic film as a substrate. The color of EBT3 Gafchromic film changes when exposed to UV light. Films were covered by sunscreen preparations of different SPF values ranging from 0 to 50. Uncovered and covered films were exposed to different solar light energies and their color change was compared. Absorbance spectra of films was measured at 633 nm using a UV-VIS spectrophotometer apparatus The color of the film darkens when UV energy increases, which means that absorbance increases with exposure time. However, when films are covered by sunscreens, the color change is less visible and the absorbance significantly decreases with increasing SPF value. There is a linear correlation between the absorbance of EBT3 Gafchromic film and SPF value of sunscreens covering the film. Statistical anal. demonstrated that the SPF value of a sunscreen can be predicted using EBT3 Gafchromic film as a substrate. This is the first report of an in vitro method based on color change of a substrate which takes into consideration exposure time, and relates more closely to conditions of real-life. Based on these parameters, this is a reliable in vitro method for SPF testing. The experimental process involved the reaction of 2-Ethylhexyl 2-cyano-3,3-diphenylacrylate(cas: 6197-30-4).COA of Formula: C24H27NO2

The Article related to sun protection factor sunscreen uv radiation ebt3 gafchromic film, gafchromic® ebt3, film dosimetry, skin protection, sun protection factor, ultraviolet radiation, Placeholder for records without volume info and other aspects.COA of Formula: C24H27NO2

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Li, Yan-An; Zhao, Xiao-Dong; Yin, Hai-Peng; Chen, Gong-Jun; Yang, Song; Dong, Yu-Bin published an article in 2016, the title of the article was A drug-loaded nanoscale metal-organic framework with a tumor targeting agent for highly effective hepatoma therapy.Computed Properties of 1312703-30-2 And the article contains the following content:

Drug delivery systems with targeting agents for precise drug release in cancer therapy are very significant and important. Herein, we report the rational design and synthesis of a DOX (doxorubicin) loaded UiO-68-type of nanoscale metal-organic framework (NMOF) with a tumor targeting agent (folic acid, FA), DOX@UiO-68-FA (3), as a multifunctional drug delivery system for hepatoma (Hep G2) therapy via tail-vein injection. Compared to free DOX, FA-unloaded DOX@Mi-UiO-68 (2), 3 exhibits a much higher antitumor efficacy, which was confirmed by cell imaging, standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) proliferation and in vivo experiments The experimental process involved the reaction of Dimethyl 2′-amino-[1,1′:4′,1”-terphenyl]-4,4”-dicarboxylate(cas: 1312703-30-2).Computed Properties of 1312703-30-2

The Article related to metal organic framework drug delivery system preparation hepatoma therapy, Pharmaceuticals: Formulation and Compounding and other aspects.Computed Properties of 1312703-30-2

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On May 14, 2015, Lin, Wenbin; He, Chunbai; Liu, Demin published a patent.HPLC of Formula: 1312703-30-2 The title of the patent was Nanoscale carriers for the delivery or co-delivery of chemotherapeutics, nucleic acids and photosensitizers. And the patent contained the following:

Nanoscale coordination polymer nanoparticles for the co-delivery of multiple therapeutic agents are described. The multiple therapeutic agents can include a combination of different chemotherapeutic agents, a combination of one or more chemotherapeutic agents and one or more nucleic acids, such as small interfering RNA (siRNA) or microRNA, a combination of one or more chemotherapeutic agents and a photosensitizer (i.e., for use in photodynamic therapy), or a plurality of different siRNAs. Pharmaceutical formulations including the nanoparticles, methods of using the nanoparticles to treat cancer, and methods of making the nanoparticles are also described. An example describes nanoscale coordination polymers made with cisplatin or oxaliplatin prodrugs and having RNAs adsorbed on the particle surface via electrostatic interactions. The experimental process involved the reaction of Dimethyl 2′-amino-[1,1′:4′,1”-terphenyl]-4,4”-dicarboxylate(cas: 1312703-30-2).HPLC of Formula: 1312703-30-2

The Article related to nanoscale carrier delivery chemotherapeutic nucleic acid photosensitizer, Pharmaceuticals: Formulation and Compounding and other aspects.HPLC of Formula: 1312703-30-2

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On April 20, 2000, Bjore, Annika; Granath, Anna-Karin published a patent.SDS of cas: 227940-70-7 The title of the patent was A dried or frozen pharmaceutical preparation containing a class III antiarrhythmic compound. And the patent contained the following:

The present invention relates to dried preparations containing a class III antiarrythmic compound in the form of crystalline or amorphous salt or any combination thereof, where the counterion is selected from pharmaceutically acceptable water-soluble organic or inorganic acids. The present invention also relates to frozen preparations containing a class III antiarrhythmic compound in the form of salt solution, where the counterion is selected from pharmaceutically acceptable water-soluble organic or inorganic acids. Preferred preparations contain a salt of the compound 3,7-diazabicyclo[3.3.1]-nonane-3-carboxylic acid 7-[(2S)-3-(4-cyanophenoxy)-2-hydroxypropyl]-1,1-dimethylethyl ester (Compound A). Further aspects of the present invention include salts of Compound A per se, processes for preparing the preparation, as well as use of the preparations for prophylaxis and/or treatment of cardiac arrhythmia. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).SDS of cas: 227940-70-7

The Article related to antiarrhythmic diazabicyclononanecarboxylate freeze dried pharmaceutical, Pharmaceuticals: Formulation and Compounding and other aspects.SDS of cas: 227940-70-7

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Lopez Rivas, Paula; Muller, Christoph; Breunig, Christian; Hechler, Torsten; Pahl, Andreas; Arosio, Daniela; Belvisi, Laura; Pignataro, Luca; Dal Corso, Alberto; Gennari, Cesare published an article in 2019, the title of the article was β-Glucuronidase triggers extracellular MMAE release from an integrin-targeted conjugate.Name: Bis(2,5-dioxopyrrolidin-1-yl) glutarate And the article contains the following content:

A non-internalizing αvβ3 integrin ligand was conjugated to the anticancer drug MMAE through a β-glucuronidase-responsive linker. In the presence of β-glucuronidase, only the conjugate bearing a PEG4 spacer inhibited the proliferation of integrin-expressing cancer cells at low nanomolar concentrations, indicating important structural requirements for the efficacy of these therapeutics. The experimental process involved the reaction of Bis(2,5-dioxopyrrolidin-1-yl) glutarate(cas: 79642-50-5).Name: Bis(2,5-dioxopyrrolidin-1-yl) glutarate

The Article related to glucuronidase extracellular mmae release integrin targeted conjugate, Pharmaceuticals: Formulation and Compounding and other aspects.Name: Bis(2,5-dioxopyrrolidin-1-yl) glutarate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Chen, Wei-Hai; Yu, Xu; Liao, Wei-Ching; Sohn, Yang Sung; Cecconello, Alessandro; Kozell, Anna; Nechushtai, Rachel; Willner, Itamar published an article in 2017, the title of the article was ATP-Responsive Aptamer-Based Metal-Organic Framework Nanoparticles (NMOFs) for the Controlled Release of Loads and Drugs.Application of 1312703-30-2 And the article contains the following content:

Nanoparticles consisting of metal-organic frameworks (NMOFs) modified with nucleic acid binding strands are synthesized. The NMOFs are loaded with a fluorescent agent or with the anticancer drug doxorubicin, and the loaded NMOFs are capped by hybridization with a complementary nucleic acid that includes the ATP-aptamer or the ATP-AS1411 hybrid aptamer in caged configurations. The NMOFs are unlocked in the presence of ATP via the formation of ATP-aptamer complexes, resulting in the release of the loads. As ATP is overexpressed in cancer cells, and since the AS1411 aptamer recognizes the nucleolin receptor sites on the cancer cell membrane, the doxorubicin-loaded NMOFs provide functional carriers for targeting and treatment of cancer cells. Preliminary cell experiments reveal impressive selective permeation of the NMOFs into MDA-MB-231 breast cancer cells as compared to MCF-10A normal epithelial breast cells. High cytotoxic efficacy and targeted drug release are observed with the ATP-AS1411-functionalized doxorubicin-loaded NMOFs. The experimental process involved the reaction of Dimethyl 2′-amino-[1,1′:4′,1”-terphenyl]-4,4”-dicarboxylate(cas: 1312703-30-2).Application of 1312703-30-2

The Article related to atp controlled release nanoparticle aptamer metal organic framework, Pharmaceuticals: Formulation and Compounding and other aspects.Application of 1312703-30-2

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On August 19, 2020, Lerchen, Hans-Georg; Stelte-Ludwig, Beatrix; Sommer, Anette; Berndt, Sandra; Rebstock, Anne-Sophie; Johannes, Sarah; Mahlert, Christoph; Greven, Simone; Dietz, Lisa; Joerissen, Hannah published an article.Category: esters-buliding-blocks The title of the article was Tailored Linker Chemistries for the Efficient and Selective Activation of ADCs with KSPi Payloads. And the article contained the following:

Several antibody-drug conjugates (ADCs) have failed to achieve a sufficiently large therapeutic window in patients due to toxicity induced by unspecific payload release in the circulation or ADC uptake into healthy organs. Herein, we describe the successful engineering of ADCs consisting of novel linkers, which are efficiently and selectively cleaved by the tumor-associated protease legumain. ADCs generated via this approach demonstrate high potency and a preferential activation in tumors compared to healthy tissue, thus providing an addnl. level of safety. A remarkable tolerance of legumain for different linker peptides, including those with just a single asparagine residue, together with a modifier of the physicochem. metabolite profile, proves the broad applicability of this approach for a tailored design of ADCs. The experimental process involved the reaction of Bis(2,5-dioxopyrrolidin-1-yl) glutarate(cas: 79642-50-5).Category: esters-buliding-blocks

The Article related to linker peptide antibody drug conjugate antitumor targeting tweakr, Pharmaceuticals: Formulation and Compounding and other aspects.Category: esters-buliding-blocks

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On June 7, 2018, Lin, Wenbin; He, Chunbai; Lu, Kuangda; Ni, Kaiyuan; Lan, Guangxu published a patent.Computed Properties of 1312703-30-2 The title of the patent was Nanoparticles for photodynamic therapy, x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof. And the patent contained the following:

Metal-organic frameworks (MOFs) comprising photosensitizers are described. The MOFs can also include moieties capable of absorbing X-rays or other ionizing irradiation energy and/or scintillation. Optionally, the photosensitizer or a derivative thereof can form a bridging ligand of the MOF. Further optionally, the MOF can comprise inorganic nanoparticles in the cavities or channels of the MOF or can be used in combination with an inorganic nanoparticle. Also described are methods of using MOFs and/or inorganic nanoparticles in photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, or in radiotherapy-radiodynamic therapy, either with or without the co-administration of one or more immunotherapeutic agent and/or one or more chemotherapeutic agent. The experimental process involved the reaction of Dimethyl 2′-amino-[1,1′:4′,1”-terphenyl]-4,4”-dicarboxylate(cas: 1312703-30-2).Computed Properties of 1312703-30-2

The Article related to mof photosensitizer nanoparticles photodynamic chemotherapy immunotherapy therapy cancer, Pharmaceuticals: Formulation and Compounding and other aspects.Computed Properties of 1312703-30-2

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics